

## REFERENCES

- American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2009;33(1):S62-9. [DOI: 10.2337/dc10-S062]
- Athauda D, Foltynie T. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease. *Neuro pharmacology* 2017 (in press). [DOI: 10.1016/j.neuropharm.2017.09.023]
- Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management. *J. Am. Coll. Cardiol.* 2007;49(6):631-42. [DOI: 10.1016/j.jacc.2006.09.046]
- Bertoluci MC, Cé GV, da Silva AM, Wainstein MV, Boff W, Puñales M. Endothelial dysfunction as a predictor of cardiovascular disease in type 1 diabetes. *World J. Diabetes* 2015;6(5):679-92. [DOI: 10.4239/wjd.v6.i5.679]
- Bisgaard LS, Bosteen MH, Fink LN, Sorensen CM, Rosendahl A, Mogensen CK, Rasmussen SE, Rolin B, Nielsen LB, Pedersen TX. Liraglutide reduces both atherosclerosis and kidney inflammation in moderately uremic LDLr-/- mice. *PLoS One* 2016;11:e0168396. [DOI: 10.1371/journal.pone.0168396]
- Brunton SA. The changing shape of type 2 diabetes. *Medscape J. Med.* 2008;10(6):143. Buchanan TA, Xiang AH, Page KA. Gestational diabetes mellitus: risks and management during and after pregnancy. *Nat. Rev. Endocrinol.* 2012;8(11):639-49. [DOI: 10.1038/nrendo.2012.96]
- Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. *Phys. Ther.* 2008;88(11):1322-35. [DOI: 10.2522/ptj.20080008]
- Chellappan DK, Yenese Y, Wei CC, Gupta G. Nanotechnology and diabetic wound healing: a review. *Endocr. Metab. Immune Disord. Drug Targets* 2017;17(2):87-95. [DOI: 10.2174/1871530317666170421121202]
- Christensen M, Bagger JI, Vilsboll T, Knop FK. The alpha-cell as target for type 2 diabetes therapy. *Rev. Diabet. Stud.* 2011;8(3):369-81. [DOI: 10.1900/RDS.2011.8.369]
- Coyne KS, Margolis MK, Kennedy-Martin T, Baker TM, Klein R, Paul MD, Revicki DA. The impact of diabetic retinopathy: perspectives from patient focus groups. *Fam. Pract.* 2004;21(4):447-53.
- Dabla PK. Renal function in diabetic nephropathy. *World J. Diabetes* 2010;1(2):48-56. [DOI: 10.4239/wjd.v1.i2.48]
- Dahiya R. Synthesis of a phenylalanine-rich peptide as potential anthelmintic and cytotoxic agent. *Acta Pol. Pharm.* 2007;64(6):509-16.
- Dahiya R. Total synthesis and biological potential of psammosilenin A. *Arch. Pharm. (Weinheim)* 2008;341(8):502-9. [DOI: 10.1002/ardp.200800006]
- Dahiya R, Gautam H. Solution phase synthesis and bio-evaluation of cordyheptapeptide B. *Bull. Pharm. Res.* 2011;1(1):1-10.
- Dahiya R, Kumar A. Synthetic and biological studies on a cyclopolypeptide of plant origin. *J. Zhejiang Univ. Sci. B* 2008;9(5):391-400. [DOI: 10.1631/jzus.B0720001]
- Dahiya R, Singh S. Synthesis, characterization, and biological activity studies on fanlizhicyclopeptide A. *Iran. J. Pharm. Res.* 2017;16(3):1176-84.
- Dahiya R, Singh S, Kaur K, Kaur R. Total synthesis of a natural cyclooligopeptide from fruits of sugar-apples. *Bull. Pharm. Res.* 2017;7(3):151. [DOI: 10.21276/bpr.2017.7.3.4]
- Daniels SR, Pratt CA, Hayman LL. Reduction of risk for cardiovascular disease in children and adolescents. *Circulation* 2011;124:1673-86. [DOI: 10.1161/CIRCULATIONAHA.110.016170]
- de Zeeuw D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?. *Kidney Int.* 2004;66(92):S2-6. [DOI: 10.1111/j.1523-1755.2004.09201.x]
- Fox CS. Cardiovascular disease risk factors, type 2 diabetes mellitus, and the framingham heart study. *Trends Cardiovas. Med.* 2010;20(3):90-5. [DOI: 10.1016/j.tcm.2010.08.001]
- Frank RN. Diabetic retinopathy. *New Engl. J. Med.* 2004;350(1):48-58. [DOI: 10.1056/NEJMra021678]
- Garber AJ. Incretin effects on  $\beta$ -cell function, replication, and mass: the human perspective. *Diabetes Care* 2011;34(2):S258-S63. [DOI: 10.2337/dc11-s230]
- Gogia S, Rao CR. Prevalence and risk factors for peripheral neuropathy among type 2 diabetes mellitus patients at a tertiary care hospital in coastal Karnataka. *Indian J. Endocrinol. Metab.* 2017;21(5):665-9. [DOI: 10.4103/ijem.IJEM\_43\_17]
- Greenwood HC, Bloom SR, Murphy KG. Peptides and their potential role in the treatment of diabetes and obesity. *Rev. Diabet. Stud.* 2011;8(3):355-68. [DOI: 10.1900/RDS.2011.8.355]
- Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. *Nat. Rev. Mol. Cell Biol.* 2008;9(5):367-77. [DOI: 10.1038/nrm2391]
- Gupta G, Dahiya R, Dua K, Chellappan DK, Tiwari J, Sharma GN, Singh SK, Mishra A, Sharma RK, Agrawal M. Anticonvulsant effect of liraglutide, GLP-1 agonist by averting a change in GABA and brain glutathione level on picrotoxin-induced seizures. *Excli J.* 2017;16:752-4. [DOI: 10.17179/excli2017-283]
- Hansen HH, Fabricius K, Barkholt P, Mikkelsen JD, Jelsing J, Pyke C, Knudsen LB, Vrang N. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease. *Brain Res.* 2016;1646:354-65. [DOI: 10.1016/j.brainres.2016.05.038]
- Herath H, Herath R, Wickremasinghe R. Gestational diabetes mellitus and risk of type 2 diabetes 10 years after the index pregnancy in Sri Lankan women-A community based retrospective cohort study. *PLoS One* 2017;12(6):e0179647. [DOI: 10.1371/journal.pone.0179647]
- Hernandez C, Bogdanov P, Corraliza L, Garcia-Ramirez M, Sola-Adell C, Arranz JA, Arroba AI, Valverde AM, Simo R. Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. *Diabetes* 2016;65(1):172-87. [DOI: 10.2337/db15-0443]
- Imamura S, Hirai K, Hirai A. The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients. *Tohoku J. Exp. Med.* 2013;231(1):57-61. [DOI: 10.1620/tjem.231.57]
- Inoue T, Inoguchi T, Sonoda N, Hendarto H, Makimura H, Sasaki S, Yokomizo H, Fujimura Y, Miura D, Takayanagi R. GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats. *Atherosclerosis* 2015;240(1):250-9. [DOI: 10.1016/j.atherosclerosis.2015.03.026]
- Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the american diabetes association (ADA) and the european association for the study of diabetes (EASD). *Diabetes Care* 2012;35(6):1364-79. [DOI: 10.2337/dc12-0413]

- Kazmi I, Rahman M, Afzal M, Gupta G, Saleem S, Afzal O, Shaharyar MA, Nautiyal U, Ahmed S, Anwar F. Anti-diabetic potential of ursolic acid stearyl glucoside: a new triterpenic glycosidic ester from *Lantana camara*. *Fitoterapia* 2012;83(1):142-6. [DOI: 10.1016/j.fitote.2011.10.004]
- Khadra A, Pietropaolo M, Nepom GT, Sherman A. Investigating the role of T-cell avidity and killing efficacy in relation to type 1 diabetes prediction. *PLoS One* 2011;6(5):e14796. [DOI: 10.1371/journal.pone.0014796]
- Kim C. Maternal outcomes and follow-up after gestational diabetes mellitus. *Diabet. Med.* 2014;31(3):292-301. [DOI: 10.1111/dme.12382]
- Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. *Pharmacol. Rev.* 2008;60(4):470-512. [DOI: 10.1124/pr.108.000604]
- King AJ. The use of animal models in diabetes research. *Br. J. Pharmacol.* 2012;166(3):877-94. [DOI: 10.1111/j.1476-5381.2012.01911.x]
- Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. *Diabetes Care* 2009;32(7):1335-43. [DOI: 10.2337/dc09-9032]
- Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the kelly west award lecture 2008. *Diabetes Care* 2010;33(2):442-9. [DOI: 10.2337/dc09-0749]
- Lauruschkat AH, Arnrich B, Albert AA, Walter JA, Amann B, Rosendahl UP, Alexander T, Ennker J. Diabetes mellitus as a risk factor for pulmonary complications after coronary bypass surgery. *J. Thorac. Cardiovasc. Surg.* 2008;135(5):1047-53. [DOI: 10.1016/j.jtcvs.2007.07.066]
- Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. *Eye Vis. (Lond)* 2015;2:17. [DOI: 10.1186/s40662-015-0026-2]
- Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. *World J. Diabetes* 2015;6(13):1246-58. [DOI: 10.4239/wjd.v6.i13.1246]
- Li P-C, Liu L-F, Jou M-J, Wang H-K. The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice. *BMC Neurosci.* 2016;17:37. [DOI: 10.1186/s12868-016-0272-9]
- Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010. *BMJ Open* 2014;4(2):e004015. [DOI: 10.1136/bmjopen-2013-004015]
- Long AN, Dagogo-Jack S. The comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. *J. Clin. Hypertens. (Greenwich)* 2011;3(4):244-51. [DOI: 10.1111/j.1751-7176.2011.00434.x]
- Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N. Engl. J. Med.* 2016;375(4):311-22. [DOI: 10.1056/NEJMoa1603827]
- Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength?. *World J. Diabetes* 2014;5(4):444-70. [DOI: 10.4239/wjd.v5.i4.444]
- Masic I, Rahimic M, Dilic M, Kadribasic R, Toromanovic S. Socio-medical Characteristics of Coronary Disease in Bosnia and Herzegovina and the World. *Mater. Sociomed.* 2011;23(3):171-83.
- Murchison AP, Hark L, Pizzi LT, Dai Y, Mayro EL, Storey PP, Leiby BE, Haller JA. Non-adherence to eye care in people with diabetes. *BMJ Open Diabetes Res. Care* 2017;5(1):e000333. [DOI: 10.1136/bmjdr-2016-000333]
- Nadkarni P, Chepurny OG, Holz GG. Regulation of glucose homeostasis by GLP-1. *Prog. Mol. Biol. Transl. Sci.* 2014;121:23-65. [DOI: 10.1016/B978-0-12-800101-1.00002-8]
- NIH. Clinical trial on treatment of diabetic neuropathy with liraglutide (TODINELI). Accessed 28/09/2017.
- Osonoi T, Saito M, Tamasawa A, Ishida H, Tsujino D, Nishimura R, Utsunomiya K. Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study. *PLoS One* 2014;9(12):e113468.
- Peters KR. Liraglutide for the treatment of type 2 diabetes: a clinical update. *Am. J. Ther.* 2013;20(2):178-88. [DOI: 10.1097/MJT.0b013e3182204c16]
- Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. *Drugs Context* 2015;4:212283. [DOI: 10.7573/dic.212283]
- Qi L, Ke L, Liu X, Liao L, Ke S, Liu X, Wang Y, Lin X, Zhou Y, Wu L, Chen Z, Liu L. Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3beta pathway in an amyloid beta protein induced alzheimer disease mouse model. *Eur. J. Pharmacol.* 2016;783:23-32.
- Rizvi AA, Patti AM, Giglio RV, Nikolic D, Amato A, Al-Busaidi N, Al-Rasadi K, Soresi M, Banach M, Montalto G, Rizzo M. Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. *Expert Opin. Biol. Ther.* 2015;15(10):1391-7.
- Rizzo M, Rizvi AA, Patti AM, Nikolic D, Giglio RV, Castellino G, Volti GL, Caprio M, Montalto G, Provenzano V, Genovese S, Ceriello A. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. *Cardiovasc. Diabetol.* 2016;15:162.
- Russo GT, Labate AM, Giandalia A, Romeo EL, Villari P, Alibrandi A, Perdichizzi G, Cucinotta D. Twelve-month treatment with liraglutide ameliorates visceral adiposity index and common cardiovascular risk factors in type 2 diabetes outpatients. *J. Endocrinol. Invest.* 2015;38(1):81-9. [DOI: 10.1007/s40618-014-0163-9]
- Ryuge A, Minoru K, Yu K, Takaya O, Masahiko Y, Makoto Y, Yukako O, Yoichiro H, Takahiro I, Tatsuhiro T, Hideaki S, Eitaro N, Yoshiro F. Examination of the effects of liraglutide on diabetic nephropathy. *Kidney Res. Clin. Prac.* 2012;31(2):A70. [DOI: 10.1016/j.krcp.2012.04.536]
- Salcedo I, Tweedie D, Li Y, Greig NH. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. *Br. J. Pharmacol.* 2012;166(5):1586-99. [DOI: 10.1111/j.1476-5381.2012.01971.x]
- Schneider C, Coll B, Jick SS, Meier CR. Doubling of serum creatinine and the risk of cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes mellitus: a cohort study. *Clin. Epidemiol.* 2016;8:177-84.
- Schwartz SS, Kohl BA. Glycemic control and weight reduction without causing hypoglycemia: the case for continued safe aggressive care of patients with type 2 diabetes mellitus and avoidance of therapeutic inertia. *Mayo Clin. Proc.* 2010;85(12):S15-S26.
- Serhiyenko VA, Serhiyenko AA. Diabetic cardiac autonomic

- neuropathy: do we have any treatment perspectives?. *World J. Diabetes* 2015;6:245-58. [DOI: 10.4239/wjd.v6.i2.245]
- Sharma S, Pathak S, Gupta G, Sharma SK, Singh L, Sharma RK, Mishra A, Dua K. Pharmacological evaluation of aqueous extract of *syzigium cumini* for its antihyperglycemic and antidyslipidemic properties in diabetic rats fed a high cholesterol diet-role of PPARgamma and PPARalpha. *Biomed. Pharmacother.* 2017;89:447-53. [DOI: 10.1016/j.biopha.2017.02.048]
- Tabit CE, Chung WB, Hamburg NM, Vita JA. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. *Rev. Endocr. Metab. Disord.* 2010; 11(1):61-74. [DOI: 10.1007/s11154-010-9134-4]
- Tamasawa A, Saito M, Ishida H, Osonoi Y, Osonoi T. The renal protective effects of liraglutide in patients with type 2 diabetes and nephropathy: a retrospective observational study. *Int. J. Diabetes Clin. Diagn.* 2017;4:124. [DOI: 10.15344/2394-1499/2017/124]
- Tan J, Zwi LJ, Collins JF, Marshall MR, Cundy T. Presentation, pathology and prognosis of renal disease in type 2 diabetes. *BMJ Open Diabetes Res. Care* 2017;5(1):e000412. [DOI: 10.1136/bmjdr-2017-000412]
- Thomas MC. The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. *Diabetes Metab.* 2017;43(1):2S20-7.
- Tiwari J, Gupta G, Dahiya R, Pabreja K, Sharma RK, Mishra A, Dua K. Recent update on biological activities and pharmacological actions of liraglutide. *Excli J.* 2017;16: 742-7. [DOI: 10.17179/excli2017-323]
- Van Buren PN, Toto R. Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. *Adv. Chronic Kidney Dis.* 2011;18(1):28-41. [DOI: 10.1053/j.ackd.2010.10.003]
- Warren TY, Barry V, Hooker SP, Sui X, Church TS, Blair SN. Sedentary behaviors increase risk of cardiovascular disease mortality in men. *Med. Sci. Sports Exerc.* 2010; 42(5):879-85. [DOI: 10.1249/MSS.0b013e3181c3aa7e]
- Yuan CM, Nee R, Ceckowski KA, Knight KR, Abbott KC. Diabetic nephropathy as the cause of end-stage kidney disease reported on the medical evidence form CM S2728 at a single center. *Clin. Kidney J.* 2017;10(2):257-62. [DOI: 10.1093/ckj/sfw112]
- Zhang W, Liu H, Al-Shabrawey M, Caldwell RW, Caldwell RB. Inflammation and diabetic retinal microvascular complications. *J. Cardiovasc. Dis. Res.* 2011;2(2):96-103. [DOI: 10.4103/0975-3583.83035]
- Zhu H, Zhang Y, Shi Z, Lu D, Li T, Ding Y, Ruan Y, Xu A. The neuroprotection of liraglutide against ischaemia-induced apoptosis through the activation of the PI3K/AKT and MAPK pathways. *Sci. Rep.* 2016;6:26859. [DOI: 10.1038/srep26859]

\*\*\*\*\*